New Agents in Multiple Myeloma: An Examination of Safety Profiles
Numerous treatments are available for relapsed and/or refractory multiple myeloma (MM), with safety profiles varying across drug classes and across agents within the same class. Thus, it is important to understand the toxicities of each antimyeloma agent when making treatment decisions. Neutropenia is commonly associated with lenalidomide and pomalidomide, and may be common with histone deacetylase (HDAC) inhibitors, but is relatively unusual with thalidomide, bortezomib, and carfilzomib. Infection was common in trials of lenalidomide and pomalidomide, and upper respiratory tract infection and pneumonia have been seen with carfilzomib.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Sara Bringhen, Edwin De Wit, Meletios-Athanassios Dimopoulos Tags: Review Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Pneumonia | Respiratory Medicine | Revlimid | Toxicology | Velcade